Leveraging AI-enhanced multi-omics discovery of novel tumor-selective targets for ADC development

TenSixty Biosciences employs an innovative AI-enhanced multi-omics discovery framework to enable the development of next-generation antibody-drug conjugates (ADCs). This integrated approach identified novel tumor-selective targets with high therapeutic potential by combining: 1. Multi-dimensional omics analysis integrated with advanced AI analytics to uncover therapeutically relevant cancer targets 2. Specialized proteomic profiling focused on unique post-translational modifications (PTMs) that reveal tumor-specific variants of targets, enabling enhanced tumor-selective targeting 3. Proprietary antibody discovery and engineering generates tumor-selective antibodies directed against these variants, yielding highly potent ADC candidates Applied to small cell lung cancer (SCLC), this framework identified a novel therapeutic target exhibiting tumor-specific hypoglycosylation. Antibodies directed against the epitope exposed by altered glycosylation showed exceptional tumor selectivity and markedly enhanced ADC efficacy. AI-driven integration across discovery and development stages further accelerated target validation and candidate optimization.